Dr Simron Singh speaks to ecancer about the results from the phase 3 Netter-2 trial which evaluates the use of radioligand therapy in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumours.

Dr Singh reports that the hazard ratio for the trial was 0.276 which was a 72% risk reduction for the radioligand therapy compared with the control arm of octreotide.

He details that the median progression-free survival for the radioligand therapy was 22.8 months compared with 8.5 months in the octreotide arm, showing a significant improvement in efficacy.